Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 12/20 | 0.55 |
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6566619 | 0.81 | KMT2A (0.51) | NPC1RAB9A | |
| SCHEMBL6566599 | 0.80 | FPR2 (0.53) | NPC1RAB9A | |
| SCHEMBL6564613 | 0.79 | HIF1A (0.50) | NPC1RAB9A | |
| SCHEMBL6566853 | 0.78 | CASR (0.53) | NPC1RAB9A | |
| SCHEMBL6566998 | 0.77 | RAB9A (0.55) | NPC1RAB9A | |
| SCHEMBL6564461 | 0.75 | RAB9A (0.50) | NPC1RAB9ACYP3A4 | |
| SCHEMBL27548486 | 0.75 | NAMPT (0.67) | QPCTNAMPTEPHX1NPC1RAB9A | |
| SCHEMBL6568007 | 0.71 | KMT2A (0.47) | RAB9A | |
| SCHEMBL30050799 | 0.69 | QPCT (0.75) | QPCTNAMPTEPHX1NPC1RAB9A | |
| SCHEMBL3628979 | 0.69 | PPARA (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | QPCT 3706/4885NAMPT 3240/4885EPHX1 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.